FY2028 Earnings Forecast for ESLA Issued By Zacks Research

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Analysts at Zacks Research issued their FY2028 EPS estimates for Estrella Immunopharma in a note issued to investors on Tuesday, July 14th. Zacks Research analyst D. Bautz anticipates that the company will earn ($0.31) per share for the year. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.39) per share.

Estrella Immunopharma (NASDAQ:ESLA) last posted its earnings results on Saturday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03.

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Stock Performance

NASDAQ ESLA opened at $0.77 on Thursday. Estrella Immunopharma has a fifty-two week low of $0.77 and a fifty-two week high of $3.15. The stock has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.21. The stock has a market cap of $33.21 million, a P/E ratio of -2.27 and a beta of 0.85.

Hedge Funds Weigh In On Estrella Immunopharma

A number of institutional investors have recently bought and sold shares of the stock. Quadrature Capital Ltd purchased a new stake in Estrella Immunopharma in the fourth quarter worth about $43,000. State Street Corp grew its holdings in shares of Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares during the period. XTX Topco Ltd raised its position in shares of Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after acquiring an additional 39,099 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Estrella Immunopharma in the 4th quarter worth approximately $88,000. Finally, Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares during the period. 0.35% of the stock is owned by institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.